reduce vascular lesion development after balloon injury in experimental studies. 13, 14 Thus, it is thought that restenosis may be prevented or minimized by the local administration of a direct thrombin inhibitor. Argatroban is a direct thrombin inhibitor that has a more potent inhibitory effect on fibrin-or clot-incorporated thrombin than other thrombin inhibitors such as heparin and hirudin. 15 , 16 Tomaru et al reported that the local delivery of argatroban using a double-balloon catheter reduced intimal thickening after balloon injury in an experimental study. 17 Accordingly, we conducted a prospective, randomized, controlled clinical trial to assess the effect of the local delivery of argatroban as a direct thrombin inhibitor using a Dispatch™ catheter system 18 (SIMED Life Systems, Inc, Maple Grove, MN, USA) in the prevention of restenosis after percutaneous coronary intervention (PCI).
Methods

Study Protocol
Between March 1995 and May 1997, 70 patients who required coronary revascularization were registered in the present trial (Drug Delivery Device in Coronary Balloon Angioplasty Trial: 3D-CAT) at the National Cardiovascular Center. The 3D-CAT is a randomized controlled pilot trial for prevention of restenosis after coronary balloon angioplasty conducted at a single center. The inclusion criterion was that the patient was scheduled for elective POBA with a balloon size equal to or larger than 2.75 mm. All of the patients had ischemic chest pain or evidence of ischemia diagnosed by a thallium-201 or treadmill exercise test. The patients were randomly assigned to 2 groups according to consecutive sealed envelopes; the control group (n=35) underwent a conventional method of POBA, and the argatroban group (n=35) had the addition of local delivery of argatroban. The exclusion criteria were (1) more than 80 years old or less than 20 years old, (2) a target lesion in a non-protected left main coronary artery, (3) a total occlusive lesion equal to TIMI 0-1 flow, (4) a severely calcified lesion, (5) a diffuse lesion, (6) a target vessel with severe proximal tortuosity, (7) a lesion that restenosed more than once, (8) a bypass graft vessel, (9) an indication for a new device (eg, directional coronary atherectomy, stent, rotational atherectomy or laser ablation), (10) poor left ventricular function (ejection fraction <40%), (11) patients receiving warfarin, (12) patients receiving an intravenous infusion of heparin, (13) a history of gastrointestinal bleeding, thrombocytopenia, or coagulopathy, (14) a history of stroke within the preceding 3 months, (15) acute myocardial infarction within the previous month, (16) patients undergoing thrombolysis within the past 24 h, (17) pregnancy, and (18) other major illness including renal failure and liver dysfunction. Informed consent was obtained from each patient.
PCI Procedure and Adjunctive Therapy
Coronary angiography was performed using the Judkins method, and a bolus of 5,000-8,000 IU heparin was given intravenously after vascular access had been established. In the control group, the POBA was performed in a standard way with a bolus injection of heparin (50 U/kg per h) during the procedure, followed by an infusion of heparin (25 U/kg per h) for 4 h after the POBA. In the argatroban group, an intravenous infusion of argatroban was given (1 g/kg per min) 30 min before POBA, followed by the local delivery of argatroban (10 mg/20 min) into the dilated site using the Dispatch™ catheter (SIMED Life Systems) after the successful POBA. Postoperatively, the patients received an intravenous infusion of argatroban (1 g/kg per min) for 4 h (Fig 1) . All patients received both Ca antagonist and 81-162 mg of aspirin before the POBA until the follow-up angiography. In addition, -blockers, long-acting isosorbide dinitrates or nicorandil was administered at the discretion of the treating physician before the POBA until the follow-up coronary angiography. Clinical success of the POBA was defined as angiographic success (residual stenosis <50%) without a major complication (death, myocardial infarction, or emergency coronary-artery bypass surgery) during hospitalization.
Quantitative Coronary Angiographic Analysis
All angiograms were analyzed by a computer-assisted system of quantitative coronary angiographic analysis (QCA; Cardiovascular Measurement System Ver. 3.0 A bolus of 5,000-8,000 IU heparin was injected intravenously at the start of the percutaneous coronary intervention (PCI) procedure. Patients were randomly assigned to 2 groups: the control group and the argatroban group receiving local delivery of argatroban via a Dispatch™ catheter after PCI. Control group: PCI was performed; the patients received a bolus injection of heparin during the procedure and an intravenous infusion of heparin for 4 h after angioplasty. Argatroban group: intravenous infusion of argatroban was started 30 min before the PCI, followed by local delivery of argatroban into the dilated site using a Dispatch™ catheter, and the postoperative treatment of intravenous infusion of argatroban for 4 h.
(CMS), Medical Imaging Systems Inc, Leiden, the Netherlands). CAG was performed before, immediately after, and 3 months after the POBA (follow-up) as described in detail elsewhere. 19 All angiographic analyses were performed in a blinded fashion by an experienced physician. The % diameter stenosis (%DS) and minimal lumen diameter (MLD) of the target lesion were determined quantitatively. The diameter of a Judkins catheter was measured using a precision micrometer (No. 293-421-20; precision 0.001 mm, Mitutoyo Co, Kawasaki, Japan) to obtain a calibration factor in the 'Free French' mode in the image calibration of the CMS program. The calibration factor (CF) was adjusted between 0.08 and 0.1 mm/pixel using digital zoom according to the CMS manual. 20 The complex edit mode (gradient field transform: GFT) was used in the case of a complex lesion, as described in detail elsewhere. 21 Angiographic restenosis after POBA was defined as a %DS greater than 50% on the follow-up angiogram. Clinical restenosis was defined as the recurrence of ischemia and/or target lesion revascularization within the period before the follow-up angiography.
Endpoints
The following endpoints were prospectively defined. Restenosis was the primary endpoint. Secondary endpoints included death, acute myocardial infarction (symptoms, ECG changes, and creatine kinase >twice the upper normal limit) and coronary revascularization (coronary bypass surgery, or repeated POBA and/or coronary stenting). Repeat revascularization of the target lesion (target lesion revascularization) was defined as angioplasty or bypass surgery performed because of restenosis of the target lesion in association with recurrent angina, objective evidence of myocardial ischemia, or both. The principal safety endpoints were abrupt vessel closure, stroke, major bleeding, or the need for vascular surgery. Major bleeding was defined as intracranial hemorrhage or overt bleeding associated with a decrease in hemoglobin of more than 5 g/dl.
Statistical Analyses
The data are presented as mean ± SD (standard deviation). Differences in angiographical parameters (%DS and MLD) between the 2 groups before POBA, immediately after all procedure and during the follow-up were compared by unpaired t-test. Statistical comparisons of differences in categorical data between the 2 groups were performed using the chi-square test. Differences were considered significant when p<0.05. The clinical follow-up analyses were performed on an intention-to-treat basis and on-treatment-analyses. Moreover, angiographic follow-up analyses were performed using on-treatment-analyses. 
Results
Patient Population (Fig 1) Four patients in the argatroban group were excluded from the follow-up CAG; 1 underwent stent implantation because of a major coronary dissection before the local delivery of argatroban, 1 had an abrupt vessel closure during the local delivery of argatroban, 1 required additional ballooning and stent implantation, and 1 refused to undergo the follow-up CAG with negative exercise thallium-201 stress imaging. Four patients in the control group were also excluded from the follow-up CAG: 3 required stent implantation because of major coronary dissection after the balloon angioplasty, and 1 had residual %DS >50% (angiographically unsuccessful). During the course of the study, 2 patients died suddenly (control 1, argatroban 1) before the follow-up angiography; the 1 in the argatroban group had cardiac sudden death after balloon angioplasty on day 60 (the patient had an old myocardial infarction with left ventricular dysfunction) and the patient in the control group died suddenly on day 60 after the balloon angioplasty (suspected rupture of a thoracic aortic aneurysm). In total, 10 patients (5 in each group) were excluded from the follow-up angiography. Tables 1 and 2 summarize the baseline clinical and lesion characteristics; there were no significant differences between the 2 groups in this study.
Baseline Clinical and Lesion Characteristics
In-Hospital Outcome
The in-hospital outcomes are summarized in Table 3 . An acute occlusion in the treated segment during the local delivery of argatroban using a Dispatch™ catheter was observed in 1 patient, requiring implantation of a PalmazSchatz stent. There were no major complications during the procedure in either group. Fig 2 compares the results of the angiographic analyses between the 2 groups. There were no significant differences between the 2 groups in %DS (Control group: 30.9±10.9%, Argatroban group: 31.7±9.6%) or MLD (Control group: 1.95±0.3 mm, Argatroban group: 1.92±0.35 mm) immediately after procedure. However, after 3 months, the angiographic parameters of %DS (Control group: 51.3±16.2%, Argatroban group: 43.5±14.6%) and MLD (Control group: 1.36±0.46 mm, Argatroban group: 1.57±0.47 mm) were marginally better in the argatroban group than in the control group (p=0.05 and p=0.09, respectively). The mean difference in coronary MLD (net gain) between the postprocedure and follow-up angiograms was 0.51±0.44 mm in the control group, and 0.72±0.50 mm in the argatroban group (p=0.09).
Quantitative CAG Analyses at Follow-up
Restenosis Rates, Target Lesion Revascularization, and Clinical Follow-up Data
Fig 3 compares the restenosis rates in the 2 groups. The lesion restenosis (%DS >50%) rates were 27% in the argatroban group and 56% in the control group (p=0.02). The clinical restenosis rates were 14% in the argatroban group and 37% in the control group (intention-to-treat analysis; Table 4 , p=0.03). The target lesion revascularization rates were 14% in the argatroban group and 34% in the control 
There were no significant differences between the 2 groups in % diameter stenosis or minimal lumen diameter immediately after PCI. Angiographic parameters including % diameter stenosis and minimal lumen diameter were marginally better in the argatroban group than in the control group at follow-up.
group (intention-to-treat analysis; Table 4 , p=0.05). Moreover, Table 5 shows the clinical outcome at follow-up of the study patients on-treatment-analysis. Seven cases (6 stent implantations and 1 unsuccessful procedure during initial angioplasty) were excluded in Table 5 according to on-treatment-analysis. The clinical restenosis rates at follow-up were 17% (n=5) in the argatroban group and 40% (n=12) in the control group according to on-treatmentanalysis after exclusion of 10 cases (n=30, respectively; p=0.04). The details of those 10 cases are as follows: 6 stent implantations during procedure, 1 unsuccessful procedure, 2 deaths, and 1 refusal of follow-up CAG.
Discussion
Previous and Present Trials Regarding the Prevention of Restenosis
No definitively effective prevention of restenosis by systemic administration of drugs has been observed in previous clinical trials. Several types of drug therapy, such as anticoagulants (heparin, warfarin) and antiplatelet therapy (aspirin, dipyridamole, ticlopidine, prostacyclin, and thromboxane A2 inhibitor), fish oil, and steroids have failed to reduce the restenosis rate in most clinical trials. [22] [23] [24] Recently, trapidil and cholesterol-lowering agents have been shown to be promising in preventing restenosis after coronary angioplasty, 25 but patients must take these drugs for several months after angioplasty.
In contrast, coronary stenting has been shown to be effective in preventing restenosis after coronary angioplasty 26, 27 and the drug eluting stent has been developed in recent years. 28 Nevertheless, adjunctive anticoagulation and/or antiplatelet therapy is required for 1 month after coronary stenting, resulting in occasional bleeding complications. Accordingly, a new procedure with a low rate of adverse effects and no need for adjunctive therapy after discharge has been sought. In the present randomized, controlled study, local delivery plus intravenous infusion of argatroban reduced both the angiographic and clinical restenosis rates after coronary angioplasty. There was no increase in bleeding risk with the argatroban treatment. The restenosis rate in the argatroban group in this trial (27%) was similar to that in the stent group of the STRESS trial (32%; NS), 27 despite the fact that the reference vessel diameter was smaller (2.89±0.39 mm) than that in the STRESS trial (3.03±0.42 mm; p=0.07). The restenosis rate in the control group in the present study was similar to that in the control group of the CAVEAT trial (56% vs 57%). 29 
Mechanism of Restenosis and Thrombin Activation
The mechanism of restenosis after PCI is considered to be a healing process after a balloon injury. Immediately after arterial injury with a balloon catheter, many factors lead to the activation of medial smooth muscle cells (SMC), but there are 3 major ones. First, elastic recoil is a pivotal factors after mechanical trauma to the abnormal vessel wall and stretching of the normal vessel wall (ie, arterial remodeling). Second, the formation of thrombus on the intimal surface and inside the disrupted plaque is an important part of the restenosis process. The intensity of thrombus formation could serve to reduce the initial gain in lumen both by adding to the plaque mass and by elaborating more growth factors. 30 Third, the most intense interest has been on the impact of mitogenic factors (basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-), and SMC-derived growth factor (SDGF)) released by platelets, monocytes, and by components of the intact parts of the vascular wall, including the SMC. In vitro and in vivo studies have shown that injury to the endothelium and the vessel wall causes increased thrombin production. 31 Thrombin, in particular, may play a significant role in the initiation of the restenosis process, because the regulation of these growth factors has been reported to be modulated by thrombin via a thrombin receptor. 32, 33 Moreover, thrombin activates a variety of vascular and inflammatory cell types that promote wound healing. 10, 32 Thus, the inhibition of the initial thrombin activation may exert a potent preventative effect on restenosis after POBA.
Direct Thrombin Inhibitors and Restenosis
The direct thrombin inhibitors, such as r-hirudin, hirulog, hirugen and D-Phe-Pro-Arg-chlorometylketone (PPACK), are expected to reduce the restenosis rate after PCI, 11, 34 and several relevant experimental studies have been performed in recent years. Rogasta et al reported that the 2-h systemic infusion of hirudin failed to reduce cell proliferation within the first 7 days, whereas the 2-h infusion of hirulog improved the late angiographic luminal dimensions and reduced the cross-sectional area narrowing by plaque in rabbits compared with heparin controls after angioplasty. 12 They suggested that (1) hirudin inhibits cellular migration rather than proliferation, and (2) hirudin reduces mural thrombosis, resulting in less thrombus incorporation into the plaque. However, Serruys et al reported that the systemic administration of r-hirudin failed to reduce restenosis in a clinical study (HELVETICA study). 35 This discrepancy between the experimental study (Rogasta et al 12 ) and the clinical study (Serruys et al 35 ) may be explained by a difference in the local concentration of hirudin at the target lesion. Accordingly, it is expected that the local delivery of a high concentration of a direct thrombin inhibitor using a drug delivery device would reduce restenosis without increasing adverse effects in the clinical setting. However, there has not a previous clinical prospective randomized trial using a direct thrombin inhibitor and a local delivery device for preventing restenosis after angioplasty.
The present study has demonstrated that the intracoronary local delivery of argatroban, in addition to a 4-h intravenous infusion, prevents restenosis following POBA.
Argatroban has been reported to inhibit platelet activation by fibrin-or clot-incorporated thrombin more effectively than does hirudin. 16 The reason that both local delivery and continuous intravenous infusion of argatroban were used in the present study was to inhibit thrombin activity, which may increase immediately after angioplasty before the local delivery of argatroban, because there was a time delay (approximately 10 min) between the first balloon inflation and the local delivery of argatroban (thrombin receptors have been reported to appear on a SMC within a few min after balloon injury 12 ). The present findings, together with the report of Rogasta et al, 13 suggest that direct thrombin inhibition may successfully inhibit cell migration in the initiation of restenosis in human patients.
Local Drug Delivery Device
Several local delivery balloon catheters have been designed. The double-balloon catheter was the first percutaneous drug delivery device. Other drug delivery devices such as the Wolinsky perforated-balloon catheter, a microporous balloon, a channel catheter, and the Transport coronary angioplasty catheter have been developed since then. More recently, the drug delivery devices known as the Infusasleeve™, a hydrogel-coated balloon, and the Dispatch™ catheter have become available. 36 The hydrogelcoated balloon does not have a perfusion port to support distal blood flow during balloon inflation. Imanishi et al reported that the local delivery of argatroban using a hydrogel-coated balloon reduced intimal thickening after balloon injury in an experimental study. 37 The Dispatch™ catheter consists of an over-the-wire, non-dilatation catheter with a spiral inflation coil and a perfusion port on its distal tip. There are several advantages of this system for the drug delivery. First, this device allows distal coronary perfusion during balloon inflation for a sufficiently longer time compared with other drug delivery catheters. Second, this system makes it easier to deliver the drug than a hydrogelcoated balloon catheter, because in the case of the hydrogel-coated balloon, the drug must first penetrate the hydrogel-balloon surface. Third, the pharmacokinetic validity of the local delivery of argatroban using a Dispatch™ catheter has been established. Anabuki et al confirmed that the local delivery of argatroban using a Dispatch™ catheter resulted in the intramural deposition of high concentration argatroban without any arterial damage. 38 This new device has been used for the prevention of reocclusion after revascularization in patients with acute myocardial infarction and unstable angina pectoris. 18, 39 However, there are no other clinical reports on the prevention of restenosis using the Dispatch™ catheter except for one small non-randomized trial. 10 Thus, this is the first prospective randomized controlled trial using the Dispatch™ catheter and argatroban to prevent restenosis following POBA. Moreover, it is expected that these local delivery devices may be available not only for direct thrombin inhibitor but also gene therapy in the future. 40 
Study Limitations
First, it is unclear whether the local delivery of argatroban using a Dispatch™ catheter is effective in patients with small vessels (<2.5 mm). Second, this study was designed as an open-label randomized trial in the light of safety concerns. Although a double-blind design may be better, it is not easy to use a specific device such as the Dispatch™ catheter in a double-blind manner. Because no obvious benefit of long-term inflation in preventing restenosis was found in a previous study, 41 the long-term inflation (20 min) with the Dispatch™ catheter is unlikely to be responsible for the significant reduction of restenosis in the present study. Third, this trial was performed at a single center, with a small number of patients. Further study is necessary with a larger number of patients in a double-blind, randomized, multicenter trial with a placebo group (local delivery of normal saline using a Dispatch™ catheter). We are now planning to conduct such a trial in Japan. Fourth, the effect of the exclusively local delivery of argatroban remains undetermined, because postoperative intravenous infusion of argatroban was combined with the intracoronary local delivery in the present study. Further study is necessary to assess the 'pure' efficacy of the local delivery of argatroban. Moreover, further study is necessary to assess the efficacy for stenting lesions in the present stenting era. Final, the present study did not evaluate local delivery direct pressure, although it is reported that high, local delivery pressure is a key determinant of vascular damage and intimal thickening. 42 Further study is needed to examine the local drug delivery pressure during infusion of argatroban in the clinical setting.
Conclusions
The local delivery of argatroban using a Dispatch™ catheter was observed to be safe and effective in preventing restenosis after balloon angioplasty.
